MaxCyte, Inc. (MXCT): Depreciation & Amortization
$4.34M
Year ended 2025-12-31
$4.17M
Trailing 12 months to 2026-06-30
+17.2%
3-year compound annual growth
+32.9%
5-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.34M | +0.6% | 2026-03-25, From 2025-01-01 |
| 2024-12-31 | $4.32M | +3.5% | 2026-03-25, From 2024-01-01 |
| 2023-12-31 | $4.17M | +54.6% | 2025-03-11, From 2023-01-01 |
| 2022-12-31 | $2.70M | +89.5% | 2024-03-12, From 2022-01-01 |
| 2021-12-31 | $1.42M | +35.9% | 2023-03-15, From 2021-01-01 |
| 2020-12-31 | $1.05M | +70.8% | 2022-03-22, From 2020-01-01 |
| 2019-12-31 | $613.5K | n/a | 2022-03-22, From 2019-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| MaxCyte, Inc. (MXCT) | 2025-12-31 | $4.34M | +0.6% |
| OmniAb, Inc. (OABI) | 2025-12-31 | $21.75M | -7.8% |
| Foxo Technologies Inc. (FOXO) | 2025-12-31 | $597.4K | -51.6% |
| NRC Health (NRC) | 2025-12-31 | $7.62M | +26.6% |
| bioAffinity Technologies, Inc. (BIAF) | 2025-12-31 | $504.8K | -16.6% |
| Absci Corp (ABSI) | 2025-12-31 | $11.74M | -12.3% |
| iSpecimen Inc. (ISPC) | 2025-12-31 | $1.73M | -24.6% |
| OneMedNet Corp (ONMD) | 2025-12-31 | $65.0K | +14.0% |
| Charles River Laboratories International, Inc. (CRL) | 2025-12-27 | $403.31M | +11.5% |
Compare MXCT, OABI, FOXO, NRC side by side · Screen every company in Services-Commercial Physical & Biological Research ↗